Literature DB >> 10904141

Decreased frontal lobe ratio of N-acetyl aspartate to choline in familial schizophrenia: a proton magnetic resonance spectroscopy study.

W Block1, T A Bayer, R Tepest, F Träber, M Rietschel, D J Müller, T G Schulze, W G Honer, W Maier, H H Schild, P Falkai.   

Abstract

Neuropathological and neuroimaging studies suggest neuronal dysfunction in schizophrenia. N-acetyl aspartate (NAA) is a useful marker of neuronal dysfunction that can be measured with magnetic resonance spectroscopy (MRS). In the present study NAA, choline (Cho), phospho-creatine ((P)Cr), inositol containing compounds and glutamine/glutamate (Glx) were assessed in the left frontal lobe and basal ganglia of subjects with familial schizophrenia, family members with mixed psychiatric diagnoses, unaffected family members, and community controls. Concentrations of metabolites were analyzed and expressed as ratios. NAA/Cho, NAA/(P)Cr and Glx containing compounds showed a negative correlation with age in the frontal lobe. After covarying for age, subjects with schizophrenia had a significant reduction in the left frontal lobe NAA/Cho ratio compared with unaffected family members (P=0.018) as well as with community non-familial (P=0.037) controls. These MRS observations support the hypothesis of a disease-related neuronal deficit in the frontal lobe of schizophrenic patients, and relatively normal basal ganglia.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10904141     DOI: 10.1016/s0304-3940(00)01264-7

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  19 in total

Review 1.  Postmortem investigations of the pathophysiology of schizophrenia: the role of susceptibility genes.

Authors:  William R Perlman; Cynthia Shannon Weickert; Mayada Akil; Joel E Kleinman
Journal:  J Psychiatry Neurosci       Date:  2004-07       Impact factor: 6.186

Review 2.  [Advances in neurobiological understanding of schizophrenia. Perspectives for new therapeutic concepts].

Authors:  P Falkai; W Maier
Journal:  Nervenarzt       Date:  2006-11       Impact factor: 1.214

Review 3.  Neurometabolites in schizophrenia and bipolar disorder - a systematic review and meta-analysis.

Authors:  Nina Vanessa Kraguljac; Meredith Reid; David White; Rebecca Jones; Jan den Hollander; Deborah Lowman; Adrienne Carol Lahti
Journal:  Psychiatry Res       Date:  2012-09-13       Impact factor: 3.222

4.  Magnetic resonance spectroscopy of limbic structures displays metabolite differences in young unaffected relatives of schizophrenia probands.

Authors:  Aristides A Capizzano; Juana L Nicoll Toscano; Beng-Choon Ho
Journal:  Schizophr Res       Date:  2011-06-25       Impact factor: 4.939

Review 5.  Glutamatergic abnormalities in schizophrenia: a review of proton MRS findings.

Authors:  Eline M P Poels; Lawrence S Kegeles; Joshua T Kantrowitz; Daniel C Javitt; Jeffrey A Lieberman; Anissa Abi-Dargham; Ragy R Girgis
Journal:  Schizophr Res       Date:  2014-01-11       Impact factor: 4.939

Review 6.  Imaging genetics of structural brain connectivity and neural integrity markers.

Authors:  Stefano Marenco; Eugenia Radulescu
Journal:  Neuroimage       Date:  2009-11-22       Impact factor: 6.556

7.  Proton magnetic resonance spectroscopy of the substantia nigra in schizophrenia.

Authors:  Meredith A Reid; Nina V Kraguljac; Kathy B Avsar; David M White; Jan A den Hollander; Adrienne C Lahti
Journal:  Schizophr Res       Date:  2013-05-21       Impact factor: 4.939

Review 8.  Advances in the treatment of anxiety: targeting glutamate.

Authors:  Asher B Simon; Jack M Gorman
Journal:  NeuroRx       Date:  2006-01

9.  Biochemical changes in the cingulum in patients with schizophrenia and chronic bipolar disorder.

Authors:  Fernando Sarramea Crespo; Rogelio Luque; David Prieto; Pablo Sau; Carmen Albert; Itziar Leal; Ana de Luxan; Maria Isabel Osuna; Miguel Ruiz; Rosa Galán; Francisco Cabaleiro; Vicente Molina
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-04-24       Impact factor: 5.270

10.  Glutamatergic antipsychotic drugs: a new dawn in the treatment of schizophrenia?

Authors:  James M Stone
Journal:  Ther Adv Psychopharmacol       Date:  2011-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.